Navigation Links
Study links molecule to muscle maturation, muscle cancer

COLUMBUS, Ohio Researchers at The Ohio State University Comprehensive Cancer Center have discovered that a molecule implicated in leukemia and lung cancer is also important in muscle repair and in a muscle cancer that strikes mainly children.

The study shows that immature muscle cells require the molecule, called miR-29, to become mature, and that the molecule is nearly missing in cells from rhabdomyosarcoma, a cancer caused by the proliferation of immature muscle cells.

Cells from human rhabdomyosarcoma tumors showed levels of the molecule that were 10 percent or less of those in normal muscle cells. Artificially raising the level of the molecule in the cancer cells cut their growth by half and caused them to begin maturing, slowing down tumor growth.

MiR-29 is a type of microRNA, a family of molecules that helps regulate the proteins cells produce. Researchers say this study is unusual because it also sheds light on the how a microRNA itself is regulated.

"This study shows that there is a connection between this microRNA, muscle development and rhabdomyosarcoma," says principal investigator Denis C. Guttridge, associate professor of molecular virology, immunology and medical genetics and a researcher with Ohio State's human cancer genetics program.

"The findings should give us a better understanding of muscle repair and development, and of rhabdomyosarcoma, and could lead to new treatments for this and other muscle diseases," he says.

The study is published in a recent issue of the journal Cancer Cell.

Guttridge and his colleagues discovered that the gene for miR-29 is silenced by the action of a protein, called NF-B (pronounced, NF kappa B). Their study shows that this protein is present at high levels in rhabdomyosarcoma cells, and that this keeps miR-29 shut off, preventing muscle progenitor cells from maturing.

When they raised the level of the microRNA molecule in the cells, or lowered the level of the NF-B protein, the cells' growth rate dropped two fold, and they began taking on the appearance of mature muscle cells. The modified cells also formed significantly smaller tumors when transplanted into an animal model than did typical rhabdomyosarcoma cells.

"High levels of the protein silence miR-29, which blocks differentiation, causing muscle cells to remain immature. If we can restore the levels of miR-29 in patients," Guttridge says, "it might provide a new therapy for this childhood cancer and perhaps other muscle diseases."


Contact: Darrell E. Ward
Ohio State University Medical Center

Related biology news :

1. Study shows competition, not climate change, led to Neanderthal extinction
2. Facial expressions of emotion are innate, not learned, says new study
3. Recipe for capturing authentic embryonic stem cells may apply to any mammal, study suggests
4. Study first to pinpoint why analgesic drugs may be less potent in females than in males
5. Study links ecosystem changes in temperate lakes to climate warming
6. New edition of laboratory manual includes cutting-edge techniques to study gene regulation
7. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
8. Scientists study how asbestos fibers trigger cancer in human cells
9. Male dinosaurs may have been prehistoric babysitters, study shows
10. Study: Did early climate impact divert a new glacial age?
11. Purdue study suggests warmer temperatures could lead to a boom in corn pests
Post Your Comments:
Related Image:
Study links molecule to muscle maturation, muscle cancer
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
Breaking Biology Technology: